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Abstract 
 The kidneys play a primary role in maintaining homeostasis and detoxification 
of diverse hydrophilic xenobiotics as well as endogenous by-products. Solute carrier 
(SLC)22A organic ion transporter family members mediate renal excretion of both 
endogenous and exogenous substances. Thus, the functional and molecular variations 
of renal SLC22A transporters under acute kidney injury (AKI) have an impact on 
systemic clearance of their substrate drugs, resulting in altered pharmacokinetics or 
unexpected adverse events caused by the accumulation of drugs. Recently, there have 
been significant advances in our understanding of the regulatory mechanisms for 
transcription, membrane trafficking and/or kidney-specific expression of 
SLC22A6/OAT1, SLC22A8/OAT3 and SLC22A2/OCT2. Hepatocyte nuclear factor 
(HNF)-1α/β and HNF-4 appear to play key roles in the transcriptional regulation of 
OAT1 and OAT3. Furthermore, OAT1 activity/function is modulated via 
phosphorylation mediated by protein kinase C (PKC) and mitogen-activated protein 
kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways. AKI affects 
renal disposition of organic ions in association with the deteriorated glomerular 
filtration and tubular transport functions. Thus, dysfunctional regulation of SLC22A 
transporters during AKI induced by ischemia or toxicants, such as cisplatin, inorganic 
mercury or uranyl nitrate, cause uremic syndromes or adverse drug reactions. Indoxyl 
sulfate, a uremic toxin and substrate of OAT1 and OAT3, appears to mediate the 
progression of AKI evoked by renal ischemia and cisplatin treatment. Precise 
mechanisms for regulation of the SLC22A transporters in AKI require studies based 
3 
 
on the transcription, trafficking, phosphorylation and endogenous factor-dependent 
modulation. Such analysis will provide a better understanding of the 
pathophysiological implications of SLC22A transporters.  
 
Keywords: SLC22A transporter family; Acute kidney injury; Ischemia/reperfusion; 
Nephrotoxicity; Indoxyl sulfate; Renal tubular secretion.  
 
Abbreviations: AKI, acute kidney injury; ARE, androgen response elements; BUN, 
blood urea nitrogen; CRE, cyclic AMP-response element; CRF, chronic renal failure; 
EGF, epidermal growth factor; ERK, extracellular signal-regulated kinase; ES, estrone 
sulfate; HNF, hepatocyte nuclear factor; IS, indoxyl sulfate; I/R, ischemia/reperfusion; 
MAPK, mitogen-activated protein kinase; NSAID, non-steroidal anti-inflammatory 
drug; MATE, multidrug and toxin extrusion; MEK, 
mitogen-activated/extracellular-signal regulated kinase kinase; OAT, organic anion 
transporter; OCT, organic cation transporter; PAH, p-aminohippuric acid; PG, 
prostaglandin; PKA, protein kinase A; PKC, protein kinase C; PMA, phorbol 
12-myristate 13-acetate; SCr, serum creatinine; SLC, solute carrier; TEA, 
tetraethylammonium; UN, uranyl nitrate. 
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1. Introduction 
The kidneys play a primary role in homeostasis and detoxification. One key 
function of the kidneys is the disposition of diverse hydrophilic xenobiotics, including 
drugs and toxins, as well as endogenous by-products. Epithelial cells in the renal 
proximal tubules mediate directional solute transport, facilitating urinary secretion of a 
wide range of organic ions (Ullrich, 1994; Pritchard & Miller, 1996; Inui et al., 2000). 
Solute carrier (SLC)22A family members mediating transport of organic anions and 
cations in renal tubular cells appear to play a pivotal role in the efficient transepithelial 
secretion of substrates (Fig. 1) (Inui et al., 2000; Koepsell & Endou, 2004；Robertson 
& Rankin, 2006). Therefore, the functional and molecular variations of renal SLC22A 
transporters in association with kidney diseases and/or injuries have an impact on 
systemic clearance of their substrate drugs, resulting in altered pharmacokinetics or 
unexpected adverse events by accumulated drugs. Investigations on regulatory 
mechanisms involved in functional activities, membrane trafficking, tissue-specific 
expression, transcription of SLC22A transporters, especially of SLC22A6/OAT1, 
SLC22A8/OAT3 and SLC22A2/OCT2, have greatly advanced our understanding of 
their physiological and pharmacological roles.  
 Acute kidney injury (AKI) is recognized as functional or structural 
disturbances of the kidney including abnormalities in blood, urine or tissues present 
for less than three months (Star, 1998). AKI can be brought about by decreased renal 
blood flow, a toxic or obstructive insult to the renal tubule, tubular interstitial 
inflammation and edema, or primary decrease in the filtering capacity of the 
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glomerulus (Shanley et al., 1986). In general, ischemia and several toxicants, including 
therapeutic drugs, account for the largest number of AKI. Ischemia and toxicants often 
combine to induce AKI in severely ill patients with conditions such as sepsis, 
hematologic cancers or acquired immunodeficiency syndrome (Thadhani et al., 1996). 
Renal ischemia-induced AKI, which is caused by a complicated interaction between 
renal hemodynamics, inflammatory cytokines, and endothelial and tubular cell injuries, 
is a major clinical issue (Schrier et al., 2004). The kidney receives about 25% of the 
cardiac output, and the majority flows into the cortex. Therefore, even a slight decline 
in renal blood flow results in hypoxic injury of the medullary region. 
Ischemia-induced renal medulla injury is of pathophysiological significance in AKI.  
Among potential nephrotoxic drugs, including aminoglycoside and 
glycopeptide antibiotics, contrast mediums, non-steroidal anti-inflammatory drugs and 
immunosuppressive drugs, cisplatin is known to cause severe AKI during treatment of 
cancer. Cisplatin is one of the most commonly used antitumor drugs for the treatment 
of several solid tumors. The nephrotoxic effect of cisplatin is cumulative and 
dose-dependent, and often requires its dose reduction or cessation of treatment. 
Therefore, an understanding of the pathological events of cisplatin-induced AKI is a 
clinical subject for developing adjunctive therapies to prevent AKI. However, there 
are few reports concerning alteration of renal solute transporters and disposition of 
xenobiotics or endogenous metabolites, including uremic toxins such as indoxyl 
sulfate (IS), as a result of cisplatin-induced AKI. 
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This review article summarizes recent findings concerning the functional and 
transcriptional regulation of renal SLC22A transporters, and addresses the 
pharmacological/toxicological implications of the altered regulation of these 
transporters brought about by AKI. 
 
2. Pharmacology and regulation of renal SLC22A transporters 
 Rat organic cation transporter OCT1, the first member of the SLC22 family of 
transporters, was originally identified by expression cloning (Gründemann et al., 
1994). A second member of this family of transporters, rat OCT2, was described two 
years later (Okuda et al., 1996). In 1997, the first organic anion transporter OAT1 was 
identified from rat and flounder (Sekine et al., 1997; Sweet et al., 1997; Wolff et al., 
1997), followed by OAT3 from rat (Kusuhara et al., 1999). Numerous studies on 
pharmacological and toxicological aspects of these SLC22A transporters have been 
conducted, thereby providing much information on their functional roles in renal 
handling and/or disposition of drugs and toxicants. In parallel, the mechanisms of 
regulation of these renal transporters have advanced from the viewpoint of 
tissue-specific expression, transcription, membrane trafficking and modulation of 
functions.  
 
2.1. SLC22A6/OAT1 
 Renal secretion of anionic xenobiotics is performed sequentially by the 
concerted function of two distinct transport steps in the basolateral membranes and 
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luminal brush-border membranes of the tubular cells (Inui & Okuda, 1998; Inui et al., 
2000). The basolateral transport step of the negatively charged anions requires the 
energy-dependent uphill uptake, as they must be transported against an electrical 
potential barrier across the membrane. As the first step towards the molecular 
characterization of organic anion transporters, Sekine et al. (1997) and Sweet et al. 
(1997) used an expression cloning technique to isolate a cDNA encoding 
p-aminohippurate (PAH, a typical substrate for the renal organic anion transport 
system)/dicarboxylate exchanging protein, which was designated as OAT1. An 
immunohistochemical study revealed that human (h)OAT1 is exclusively expressed in 
the renal proximal tubules, being localized to the basolateral membranes 
(Hosoyamada et al., 1999; Motohashi et al., 2002). The uptake rate of PAH was 
markedly enhanced in the presence of an outward gradient of dicarboxylate, such as 
α-ketoglutarate. rOAT1 exhibited a multispecificity for endogenous anions, such as 
cyclic nucleotides, prostaglandins (PG) and uric acid, as well as toxins and structurally 
diverse drugs, such as β-lactam antibiotics, methotrexate and nonsteroidal 
anti-inflammatory drugs (NSAIDs) (Uwai et al., 1998; Tsuda et al., 1999; Sekine et al., 
2000; Burckhardt & Burckhardt, 2003; Sweet, 2005; Rizwan & Burckhardt, 2007).  
 The SLC22A OAT family isoforms possess common structural features, 
including 12 transmembrane domains flanked by intracellular N- and C-termini; 
multiple glycosylation sites located in the first extracellular loop between 
transmembrane domains 1 and 2; and potential phosphorylation sites localized in the 
intracellular loop between transmembrane domains 6 and 7 and in the C-terminus 
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(Burckhardt & Wolff, 2000; Dantzler & Wright, 2003). Recent studies concerning 
structure-function relationship of OAT isoforms suggested that glycosylation is 
essential for the adequate trafficking of these transporters to the plasma membrane 
(Tanaka et al., 2004). In addition, protein kinase C (PKC) activation was shown to 
result in a downregulation of organic anion transport activity in the isolated renal 
tubules, cultured renal cells (OK) (Nagai et al., 1997) and/or the cells transfected with 
OAT1 (Lu et al., 1999). Several mechanisms by which PKC could modulate OAT1 
activity have been proposed.  
Previous reports suggested that PMA and other PKC modulators failed to activate the 
phosphorylation of OAT1 under various experimental situations, demonstrating that 
direct phosphorylation may not evoke PKC-induced downregulation of OAT1 activity. 
Wolff et al. (2003) suggested that PKC-induced hOAT1 downregulation is achieved 
through carrier retrieval from the cell membrane and does not involve phosphorylation 
of the predicted classic hOAT1 PKC consensus sites. Kinetic analysis revealed that the 
decreased transport activity of OAT1 induced by PKC activation was associated with a 
reduced maximal transport velocity Vmax, without significant change in the substrate 
affinity Km. Direct phosphorylation of OAT1 protein by PKC could cause changes in 
the turnover of the transporter, i.e., downregulation, without the substrate affinity. 
Thus, PKC-mediated downregulation of OAT1 activity could result from 
internalization of the transporter and/or suppression of the recruitment of the matured 
transporter into the target membrane. PKC could phosphorylate protein(s) modulating 
OAT1 in the trafficking pathway. Recently, several hOAT1-interacting proteins have 
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been isolated (Zhang et al., 2008). They showed that transfection of dominant negative 
mutant of dynamin-2 into the COS-7 cells reduced the amount of surface-labeled 
OAT1 internalized both in the presence and in the absence of PMA as compared with 
that of the control (Fig. 2). The study assumed constitutive OAT1 trafficking between 
cell membrane and recycling endosomes, PKC activated-downregulation of OAT1 
activity, and OAT1 internalization partly through a dynamin and clathrin-dependent 
pathway (Zhang et al., 2008). 
 By using cultured renal epithelial OK cells, Sauvant et al. (2003) reported that 
epidermal growth factor (EGF) stimulates basolateral PAH uptake through the 
mitogen-activated protein kinase (MAPK) pathway via sequential activation of 
mitogen-activated/extracellular-signal regulated kinase kinase (MEK) and 
extracellular signal-regulated kinase isoforms 1 and 2 (ERK1/2). The stimulation of 
PAH uptake induced by EGF was completely inhibited by MEK inhibitors, such as 
PD98059 or U0126. Phosphorylation of ERK1/2 in OK cells by treatment with EGF 
was abolished by inhibiting MEK. Indeed, inhibition of MEK results in a similar effect 
on PAH transport. Using a series of inhibitors and an assay for arachidonic acid release, 
Sauvant et al. (2003) concluded that EGF activated MEK, ERK1/2 and phospholipase 
A2 (PLA2), resulting in an increased release of arachidonic acid. Subsequently, 
arachidonic acid is metabolized to prostaglandins by the action of cyclooxygenase 1, 
which then causes EGF-induced stimulation of basolateral PAH transport. In isolated 
rabbit S2 proximal tubule segments, prostaglandin E2 (PGE2) stimulated basolateral 
PAH uptake and this stimulation is suppressed by the PKA inhibitor H89. Thus, it was 
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suggested that basolateral PAH transport, presumably OAT1 activity, is 
downregulated by activation of PKC and upregulated via MAPK through PLA2, PGE2, 
cyclic AMP and PKA activation. EP4 receptor was suggested to be a candidate of 
PGE2 action for the regulation of organic anion transporter(s) in renal tubular cells. 
 It has been proposed that hOAT1 undergoes transcriptional regulation. 
Ogasawara et al. (2007) reported that hepatocyte nuclear factor (HNF)-4α markedly 
transactivated the OAT1 promoter (Fig. 3). A deletion analysis of the OAT1 promoter 
revealed that the regions spanning -1191 to -700 base pairs (bp) and -140 to -79 bp 
appeared to be essential for the transactivation by HNF-4α. These regions contained a 
direct repeat separated by two nucleotides (DR-2), which is one of the consensus 
sequences binding to HNF-4α, and an inverted repeat separated by eight nucleotides 
(IR-8), which was recently identified as a novel element for HNF-4α, respectively. By 
using an electrophoretic mobility shift assay, HNF-4α was shown to bind to DR-2 and 
IR-8 in association with HNF-4α overexpression. Under normal conditions HNF-4α 
binds to IR-8. A mutation in IR-8 markedly reduces the promoter activity, suggesting 
that HNF-4α regulates the basal transcription of OAT1 through IR-8. In contrast, Saji 
et al. (2008) suggested that HNF-1α plays an essential role in the transcriptional 
regulation of human and mouse OAT1 expression. They suggested that 
HNF-1α/HNF-1β heterodimer plays an important role in the constitutive expression of 
human and mouse OAT1 genes. Because the transcriptional activation by HNF-1α 
appears to be a common feature of OAT1 and OAT3, this transcription factor might be 
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involved in the physiological regulation of endobiotics and/or xenobiotics transport in 
the kidney.  
 
2.2. SLC22A8/OAT3 
 rOAT3 was originally identified from rat brain by using a RT-PCR cloning 
strategy based on the sequence conserved between rOAT1, rOAT2 and the rat organic 
cation transporter (Kusuhara et al., 1999). Indeed, rOAT3 exhibits 49, 39 and 36% 
identity with rOAT1, rOAT2 and rOCT1, respectively. rOAT3 mRNA appeared to be 
expressed in the liver, brain, kidney and eye. It has been proposed that rOAT3 
mediates the uptake of anionic substrates from the blood across the basolateral 
membrane into the proximal tubule cells in exchange for cytoplasmic dicarboxylates 
(Sweet et al., 2003).  
 The physiological function of OAT3 was assumed to be the secretion of both 
steroid hormones, and their corresponding conjugates, as well as prostaglandins. 
OAT3 expressed in brain and kidneys could cooperate in the removal of anionic 
neurotransmitter metabolites. hOAT3 was reported to be localized at the basolateral 
membranes of human kidney (Motohashi et al., 2002) where it is responsible for the 
transport of several substrates including the second messenger cAMP; the hormones 
cortisol, PGE2 and F2α; the conjugated hormones dehydroepiandrosterone sulfate, 
estrone sulfate (ES) and estradiol-17ß-glucuronide; the bile salt taurocholate; and the 
purine metabolite urate. The transport ability for corticosterone, ES, 
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estradiol-17ß-glucuronide and taurocholate distinguishes OAT3 from OAT1 
(Burckhardt & Burckhardt, 2003; Rizwan & Burckhardt, 2007).  
 OAT3-knockout mice are fertile and have a normal appearance, with no 
detectable tissue abnormalities in the kidneys, liver and brain. The uptake of 
taurocholate, ES and bromosulfophthalein into kidney slices from the OAT3-knockout 
mice was reduced, as was the uptake of fluorescein into cells of the choroid plexus 
(Sweet et al., 2002). rOAT3 mediated uptake of organic anions such as PAH (Km 
value of 65 μmol/L), ochratoxin A (Km value of 0.74 μmol/L) and ES (Km value of 2.3 
μmol/L). Moreover, rOAT3-mediated uptake of ES was inhibited by other anions such 
as sulfobromophthalein, probenecid, indocyanine green, bumetanide, piroxicam, 
furosemide, azidodeoxythymidine and benzylpenicillin, but not by cationic 
compounds such as tetraethylammonium (TEA), guanidine or quinidine (Kusuhara et 
al., 1999). 
 OAT3 isoforms in different species consist of 536-542 amino acids, exhibiting 
12 trans-membrane domains with a large extracellular loop between transmembrane 
domain 1 and 2, and a large intracellular loop between transmembrane domain 6 and 7 
possessing potential phosphorylation sites to be regulated by protein kinases 
(Robertson & Rankin, 2006; Rizwan & Burckhardt, 2007). PKC activation resulted in 
an inhibition of rOAT3 activity probably by induction of internalization. Experiments 
conducted using intact renal proximal tubules indicated that OAT3-mediated organic 
anion transport was downregulated by both direct and indirect (physiological) 
activation of PKC (Soodvilai et al., 2004). In contrast, OAT3 activity was upregulated 
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by EGF through activation of the MAPK pathway and subsequently through PKA 
activation (Fig. 4). Using a functional promoter assay of human OAT3, Ogasawara et 
al. (2006) demonstrated that cAMP-response element (CRE) could be essential for the 
basal and inducible promoter activity of OAT3. Furthermore, CREB-1 and ATF-1 
were found to bind to CRE, thereby activating the transcription of the OAT3 gene for 
constitutive expression. PKA further activates the transcription of the OAT3 gene 
through phosphorylation of both CREB-1 and ATF-1 for inducible expression (Fig. 5). 
 The mechanism underlying the proximal tubule-restricted expression of 
hOAT3 in the kidney is still not fully understood. Kikuchi et al. (2006) reported that 
the expression of hOAT3 is positively regulated by HNF-1α and HNF-1β and 
negatively regulated by DNA methylation, suggesting that the coordinated action of 
genetic and epigenetic factors are involved in the tissue-specific expression of hOAT3.  
 
2.3. SLC22A2/OCT2 
 In the renal tubules, organic cation transporters play physiological and 
pharmacological roles in the reabsorption and/or excretion of endogenous organic 
cations such as guanidine, choline, N1-methylnicotinamide, neurotransmitter 
monoamines (dopamine, epinephrine, and histamine) (Busch et al., 1998), cationic 
drugs (TEA, cimetidine, procainamide, and quinidine) and toxins (Inui & Okuda, 
1998; Inui et al., 2000). Organic cation transport activity is localized predominantly in 
renal proximal tubules, but has also been detected in distal tubules and collecting ducts. 
Functional studies using isolated renal tubules, stop-flow microperfusion of proximal 
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tubules, and isolated membrane vesicles, suggested that renal secretion of cationic 
substances is performed by the concerted function of two distinct organic cation 
transporters: one facilitated by the electrical potential difference at the basolateral 
membranes and the other driven by the H+ gradient at the brush border membranes 
(Holohan & Ross, 1981; Hsyu & Giacomini, 1987; Wright & Wunz, 1987; Miyamoto 
et al., 1989; Montrose-Rafizadeh et al., 1989; Sokol & McKinney, 1990; Groves et al., 
1994). Using isolated brush-border membrane vesicles and cultured renal epithelial 
cell lines, such as LLC-PK1 cells, the transport system in these membranes appeared to 
be mediated by an electroneutral H+/organic cation antiporter energized by 
transmembrane H+ gradient, which can be sustained by the Na+/H+ exchanger and/or 
H+-ATPase (Takano et al., 1984; Inui et al., 1985; Saito et al., 1992; David et al., 1995). 
The H+/organic cation antiporter in renal brush-border membranes has been proposed 
to mediate directional excretion of cationic drugs or toxins out of renal tubular cells. 
Recently, the apical type of H+/organic cation antiporter, rat multidrug and toxin 
extrusion (MATE1/SLC47A1) have been identified and functionally characterized 
(Otsuka et al., 2005; Terada et al., 2005). rMATE1 appeared to be expressed mainly in 
the kidney, where it mediates the final step of urinary excretion of cationic drugs. In 
addition, Masuda et al. (2006) identified multidrug and toxin extrusion 2 
(hMATE2-K), a novel human kidney-specific H+/organic cation antiporter that is 
responsible for the tubular secretion of cationic drugs across the brush border 
membranes.  
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 Gründemann et al. (1994) identified the first member of the organic cation 
transporter family, designated as OCT1, from the rat kidney by expression cloning. 
rOCT1 is comprised of 556 amino acids with 12 putative transmembrane domains. 
Immunohistochemical analysis revealed that rOCT1 was localized to the basolateral 
membranes of S1 and S2 segments of proximal renal tubules and the small intestine 
and liver. Electrophysiological studies using rOCT1-expressing oocytes under 
voltage-clamped conditions demonstrated that positive inward currents were induced 
when TEA, NMN, choline or dopamine was added to the bath medium (Busch et al., 
1996). Moreover, electrogenic transport was found for TEA uptake in the renal 
basolateral membranes (Busch et al., 1996). The presence of a kidney-specific organic 
cation transporter was deduced, based on pharmacokinetic behavior of various 
cationic drugs. Hybridization techniques using rOCT2 as a probe identified a cDNA 
encoding OCT2 from rat kidney (Okuda et al., 1996). rOCT2 is comprised of 593 
amino acids with 12 proposed putative transmembrane domains showing a 67% 
identity to rOCT1. The rOCT2 mRNA transcript was detected predominantly in the 
kidney, at higher levels in the medulla than the cortex, but not in the liver, lung or 
intestine (Okuda et al., 1996). TEA uptake by rOCT2-transfected MDCK cells grown 
on microporous membrane filters was markedly enhanced when TEA was added to the 
basolateral bath medium, but not to the apical medium (Urakami et al., 1998). 
Structurally diverse organic cations, including the type 1 cations such as cimetidine, 
NMN, nicotine and procainamide, and type 2 cations, such as quinine and quinidine, 
inhibited TEA uptake in the transfectants. Inhibition studies suggested that rOCT1 and 
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rOCT2 had similar inhibitor binding affinities for many compounds, but showed 
moderate differences in inhibitor sensitivity for several compounds such as MPP, 
procainamide, dopamine, and testosterone i.e., by a factor of 2 to 3. rOCT2 and 
hOCT2, which share 80% amino acid identity, appeared to recognize monoamine 
neurotransmitters such as dopamine, norepinephrine, epinephrine, 
5-hydroxytryptamine and amantadine (Gründemann et al., 1998; Urakami et al., 1998; 
Koepsell et al., 1999; Okuda et al., 1999). OCT2 has been proposed to play a 
physiological role in renal disposition of some bioactive monoamines, implying that 
OCT2 might function as a clearance transporter for these monoamines. 
 It was reported that the uptake of tetraethylammonium was greater in renal 
cortical slices of male rats than female rats, suggesting gender differences in the 
basolateral membrane transport activity for organic cations (Urakami et al., 1999). A 
previous study reported that the expression level of rOCT2, but not rOCT1 and rOCT3, 
in the kidney was much higher in males than females (Urakami et al., 1999). This 
finding suggests that rOCT2 is responsible for the gender differences in renal 
basolateral organic cation transport activity. Furthermore, treatment of male and 
female rats with testosterone significantly increased rOCT2 expression in the kidney 
(Urakami et al., 2000). hOCT2 mRNA levels were increased significantly following 
exposure of MDCK to the steroid hormones, dexamethasone (2.0-fold), 
hydrocortisone (2.4-fold) or testosterone (1.8-fold). It was proposed that steroid 
hormones induce the transcription of OCT2 in the kidney, which plays a pivotal role in 
the transcriptional regulation of the rOCT2 gene (Shu et al., 2001). Asaka et al. (2007) 
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reported that rOCT2 promoter activity was stimulated by testosterone. This 
stimulation was blocked by nilutamide, an antiandrogen agent. Reporter assays using 
deletion constructs and mutational constructs of putative androgen response elements 
(ARE) in the rOCT2 promoter region revealed that two AREs, located at 
approximately 3000 and 1300, respectively, play an essential role in the induction by 
testosterone (Fig. 6) (Asaka et al., 2006). Testosterone induces the expression of 
rOCT2, but not of rOCT1 and rOCT3, via the AR mediated transcriptional pathway. 
 Rabbit OCT2-mediated organic cation transport in stable transfectants and  
intact renal tubules was influenced by MAPK and PKA activity (Soodvilai et al., 2007). 
Activation of these protein kinases resulted in stimulation of OCT2 activity whereas 
inhibition led to depression of OCT2 activity. Regulation of OCT2 was similar to that 
observed for OAT1 and OAT3. These findings suggest that regulation of renal tubular 
transport of organic anions and cations involves a common MAPK and PKA pathway. 
 OCT2 appears to be expressed almost exclusively in the kidney, but not in the 
liver. The regulatory mechanisms involved in this kidney-specific expression of OCT2 
has been explored. Aoki et al. (2008) reported the in vivo methylation status of the 
proximal promoter region of OCT2 by using bisulfite sequencing of human genomic 
DNA extracted from the kidney and liver. All CpG sites in the OCT2 proximal 
promoter were hypermethylated in the liver, but hypomethylated in the kidney. In 
contrast, the promoter region of OCT1 was hypermethylated in both the kidney and 
liver. The level of methylation of the OCT2 promoter was especially low at the CpG 
site in the E-box, which is the binding site of the basal transcription factor upstream 
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stimulating factor (USF) 1. In vitro methylation of the OCT2 proximal promoter 
dramatically reduced the transcriptional activity, and an electrophoretic mobility shift 
assay showed that methylation at the E-box inhibited the binding of USF1 (Aoki et al., 
2008). These results suggested that kidney-specific expression of human OCT2 is 
regulated by the methylation status of the proximal promoter region, which may 
interfere with transactivation by USF1. In addition, USF-1 appeared to function as a 
basal transcriptional regulator of the hOCT2 gene via the E-box, suggesting the 
cis-elements and trans-factors are necessary for regulation. 
 
3. Altered regulation of SLC22A transporters in kidney diseases 
 Functional disturbances in renal excretion of organic ions may be of clinical 
importance, especially in the use of drugs with high toxicity or narrow therapeutic 
range. Serious kidney diseases, such as AKI, have an impact on renal disposition of 
diverse organic ions in association with decreased glomerular filtration and tubular 
transport functions. Altered regulation of renal SLC22A transporters and its impact on 
pharmacokinetics of their substrate drugs have progressed, in conjunction with 
physiological and pathological roles of uremic toxins in kidney injuries. 
 
3.1. Ischemia/reperfusion-induced AKI 
 Ischemia/reperfusion (I/R)-induced AKI is a crucial clinical issue (Star, 1998; 
Schrier et al., 2004). I/R-induced AKI is evoked by a complicated interaction between 
renal hemodynamics, inflammatory cytokines, and endothelial and tubular cell injury 
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(Thadhani et al., 1996; Kribben et al., 1999). Although the kidney receives about 25% 
of the cardiac output, the majority goes to the cortex. Therefore even a slight decline in 
renal blood flow results in hypoxic injury of the medullary region. I/R-induced injury 
to the renal medulla plays a significant role in AKI. In fact, the S3 segment of the 
proximal tubule in the outer medulla has been shown to be the most susceptible portion 
of the kidney to I/R-induced AKI. The serum level of the uremic toxin indoxyl sulfate 
(IS) is markedly elevated in uremic patients and in 5/6 nephrectomized rats, a well 
established animal model for chronic renal failure (CRF) (Enomoto & Niwa, 2007). IS 
appears to be a substrate for OAT1 and OAT3 (Deguchi et al., 2002, 2004, 2005). In 
the 5/6 nephrectomized rats, the expression of rOAT1 and rOAT3 was markedly 
downregulated in the kidney of CRF (Ji et al., 2002). In the clinical situation, patients 
with renal disease showed a downregulation of hOAT3, which is thought to be 
responsible for a decreased urinary excretion of cefazolin, an anionic cephalosporin 
antibiotic (Sakurai et al., 2004, 2005).  
 Histological examination of kidneys from rats with AKI showed that tubular 
necrosis occurred in sporadic renal epithelial cells. AKI is characterized by tubular 
dysfunction with impaired sodium and water reabsorption, which is associated with 
the shedding and excretion of brush-border membranes and tubular cells into the urine. 
Following I/R, morphological changes occur in the proximal tubules, including loss of 
cell polarity and brush border structure, and redistribution of integrins and 
Na+/K+-ATPase along the apical membrane (Molitolis et al., 1992). Because renal 
tubular secretion of xenobiotics and endogenous uremic toxins is performed by 
21 
 
organic ion transporters normally localized at the basolateral and brush border 
membranes, renal tubular dysfunction will adversely affect excretion of these 
compounds.  
 Recently, Matsuzaki et al. (2007) suggested that the serum IS level is markedly 
elevated in ischemic rats with I/R-induced AKI. IS has been shown to induce several 
genes, including transforming growth factor (TGF)-β1 and tissue inhibitor of met 
alloproteinase (TIMP)-1, thereby accelerating the progression of renal sclerosis in 
subtotal nephrectomized rat kidney (Miyazaki et al., 1997, 2000; Aoyama et al., 2003). 
The increased serum IS in ischemic AKI rats appeared to enhance acute renal tubular 
dysfunction. Because >95% of serum IS is bound to albumin, IS is excreted mostly 
into urine via tubular secretion, rather than glomerular filtration. Renal OAT1 and 
OAT3 have been reported to mediate IS uptake into renal tubular cells (Enomoto et al., 
2002).  
 Inulin and PAH clearance, along with PAH net secretion, were initially 
diminished after I/R injury but gradually recovered during follow-up. This initial 
impairment after AKI was accompanied by decreased mRNA and protein levels of 
OAT1 and OAT3 in clamped rats compared with control rats. The subsequent 
improvement of renal function was mirrored by an upregulation in the expression of 
both OAT1 and OAT3 during follow-up. Thus decreased expression of OAT1 and 
OAT3 could account for the reduced level of PAH secretion after ischemic AKI. As a 
consequence, the biological effects of endogenous anions may be affected in ischemic 
AKI. The renal tubular elimination of prostaglandin E2 appeared to be inhibited after 
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AKI, presumably preventing a washout of prostaglandin E2 and thereby suggesting a 
rescue mechanism for maintenance of renal circulation after ischemic injury.  
 The expression of rOAT1 and rOAT3 at both the mRNA and protein level were 
downregulated in ischemic rat kidney (Fig. 7) (Schneider et al., 2007; Matsuzaki et al., 
2008). In parallel, organic anion transport activity at the basolateral membrane was 
significantly reduced in the ischemic rat kidney, which was evaluated by the reduced 
accumulation of PAH and ES into renal slices. Kwon et al. (2008) reported the altered 
distribution of OAT1 after ischemia/reperfusion of rat kidney using confocal 
microscopy with a three-dimensional reconstruction of serial optical images. OAT1 
was distributed to basolateral membranes of proximal tubule cells in controls, whereas 
OAT1 decreased in basolateral membranes, especially in the lateral membrane domain, 
and appeared diffusely in cytoplasm of ischemia/reperfusion kidney. OAT1 mediates 
renal tubular uptake of several pharmacological agents, such as methotrexate, β-lactam 
antibiotics and NSAIDs, whereas OAT3 appeared to efficiently mediate ES transport 
with relatively high affinity in addition to several anionic compounds such as PAH, 
methotrexate, PGE2 and cAMP (Burckhardt & Burckhardt, 2003). Therefore, 
downregulation of both rOAT1 and rOAT3 should account for the decrease in PAH 
and ES uptake at the basolateral membrane of tubular cells in ischemic kidney. 
Alternatively, the driving force of rOAT1 and rOAT3 activity may be unbalanced in 
renal tubular cells of I/R kidney. rOAT1 and rOAT3 appeared to mediate exchange of 
anionic substrates with dicarboxylic acids, including α-ketoglutarate, where its 
cytoplasmic concentration is much higher than in the serum, thereby producing an 
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outward-directed driving force for influx of anionic substrates. The Na+/K+-ATPase 
actively pumps Na+ out of the renal proximal tubule cells thereby sustaining an 
inwardly directed Na+ gradient. The inward movement of Na+ drives the uptake of 
α-ketoglutarate by a Na+/dicarboxylate cotransporter. Decreased expression of 
Na+/K+-ATPase in the ischemic kidney (Van Why et al., 1994) could collapse the 
inward Na+ gradient, thereby reducing uptake of α-ketoglutarate via the 
Na+/dicarboxylate cotransporter. In ischemic renal tubules the driving force may be 
disturbed, thereby resulting in reduced uptake of IS via rOAT3. The precise 
mechanism involved in the relationship between the levels of serum IS and the 
expression levels of OATs and the I/R-induced downregulation of these transporters 
remains to be clarified.   
 A previous report suggested that the clinical pharmacokinetics of famotidine, a 
histamine H2-receptor blocker, is related to renal function (Inotsume et al., 1989). In 
ischemic rats, the renal excretion of famotidine was significantly reduced (Matsuzaki 
et al., 2008). A transport study demonstrated that famotidine was a substrate for 
rOCT1, rOCT2 and rOAT3 (Tahara et al., 2005). Michaelis-Menten constant (Km) 
values of famotidine for rOCT1, rOCT2 and rOAT3 were 87, 61 and 345 μM, 
respectively (Tahara et al., 2005). The maximum plasma concentrations of famotidine 
in sham-operated and I/R rats were estimated to be 154 and 148 μM, respectively 
(Matsuzaki et al., 2008). Taking these observations into consideration, the reduced 
renal excretion of famotidine in I/R may be caused by the diminished organic cation 
transport activity of the renal basolateral membrane. Using Western blot and Northern 
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blot analyses, the expression of rOCT2, but not rOCT1, appeared to significantly 
decrease in I/R rat kidneys, suggesting that rOCT2 was more sensitive to AKI (Fig. 7) 
(Matsuzaki et al., 2008). It was reported that the expression of rOCT2 was 
downregulated in rats with chronic renal failure (Ji et al., 2002). Urakami et al. (2000) 
reported that the expression of rOCT2 was upregulated by testosterone and 
downregulated by estradiol in rats. The lower plasma concentration of testosterone 
was responsible for the decreased rOCT2 expression (Ji et al., 2002). Furthermore, 
testosterone induced the expression of rOCT2, but not rOCT1 and rOCT3, via the 
androgen receptor-mediated transcriptional pathway (Asaka et al., 2006). However, 
there were no significant changes in plasma testosterone and estradiol in I/R-induced 
AKI (Park et al., 2004; Shim et al., 2009), although the serum testosterone level was 
decreased in bilateral ureteral ligation and uranyl nitrate or cisplatin-induced AKI 
(Masubuchi et al., 2006). Therefore, further studies are required to explore the 
factor(s) involved in the reduced expression of OCT2 in order to understand its 
regulation in AKI.  
 In rats with ischemic AKI, renal clearance of both famotidine and TEA was 
significantly reduced (Matsuzaki et al., 2008). Renal clearance of famotidine and TEA 
may be affected by organic cation transport activity not only at the basolateral 
membranes but also at the brush-border membranes. In the 5/6 nephrectomized rats 
exhibiting chronic kidney disease, the downregulated expression of apical rMATE1 
was correlated with the tubular secretion of cimetidine, in association with the 
depressed expression of NHE3 (Nishihara et al., 2007). TEA and cimetidine are 
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substrates for rMATE1 (Terada et al., 2005), although the ability of rMATE1 to 
recognize famotidine as a substrate has not yet been confirmed. In ischemic AKI rats, 
expression of rMATE1 at both the protein and mRNA level was markedly reduced. 
Previously, it was reported that NHE3 expression was markedly depressed in ischemic 
AKI rats, and the transport activity of organic cations in renal brush-border 
membranes was decreased in I/R rats (Maeda et al., 1993; Kwon et al., 2000). 
Therefore, the downregulation of rMATE1 could be involved in the reduced renal 
clearance of organic cations in I/R rats at the luminal membranes, as well as rOCT2.  
 
3.2. Drugs and Toxicants-induced AKI 
 Renal proximal tubules are primary sites for the active secretion of drugs, 
toxicants and endogenous metabolites into the urine. During the development of AKI 
brought about by exposure to nephrotoxic drugs or toxicants, glomerular filtration 
and/or renal secretion become unbalanced. This often requires reducing the dose 
and/or lengthening dosing intervals for therapeutics. Among such nephrotoxic 
xenobiotics, studies into the effects of cisplatin, uranyl nitrate and inorganic mercury 
on the regulation of renal SLC22A transporters have been performed.  
 
3.2.1. Cisplatin 
 Although cisplatin is an effective antineoplastic drug for the treatment of solid 
tumors, its clinical use is often limited because of adverse effects on renal function. 
Nephrotoxicity can be observed in as many as 38% of patients after a single dose of 
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cisplatin (100 mg/m2 body surface area) (Shord et al., 2006). This nephrotoxic action 
often delays subsequent chemotherapy protocols, thereby reducing the overall 
therapeutic efficacy of cisplatin. It has been demonstrated that exposure to cisplatin 
leads to necrosis as well as apoptosis of renal proximal tubule cells, with occasional 
damage to the distal tubules. Previous reports demonstrated the involvement of rat and 
human OCT2 in the cellular accumulation of cisplatin (Ciarimboli et al., 2005; 
Yonezawa et al., 2005). Interestingly, administration of a single toxic dose of cisplatin 
to rats reduces OCT2 mRNA levels after seven days, suggesting a defense response 
against subsequent exposure and renal accumulation of cisplatin. Aleksunes et al. 
(2008) reported that cisplatin-induced renal injury increased mRNA and protein levels 
of the efflux transporters Mrp2, Mrp4, Mrp5, Mdr1a and Mdr1b in mice. By contrast, 
the expression of Oat1, Oat2, Oct2 and Oatp1a1 mRNA was reduced in 
cisplatin-treated mice.  
 Morisaki et al. (2008) suggested the pathophysiological role of IS in the 
development and progression of cisplatin-induced AKI. Although anionic uremic 
toxins, such as IS, hippurate, indoleacetate and 
3-carboxy-4-methyl-5-propyl-2-furanpropionate, which are derived from dietary 
proteins, are mainly excreted into the urine, they accumulate to a high degree in the 
plasma of patients with kidney diseases (Boumendil-Podevin et al., 1975). A recent 
report suggests that uremic toxins accelerate the progression of renal injury by 
damaging tubular cells (Niwa et al., 1997). IS is produced enzymatically in the liver 
from indole, which is generated from tryptophan by the intestinal flora. In normal 
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kidney function, IS is efficiently excreted into the urine primarily by renal tubular 
secretion via organic anion transporters. This excretion pathway maintains the serum 
level of IS at approximately 4 μM. Oral administration of IS in uremic rats stimulates 
glomerular sclerosis, which is accompanied by a reduction in renal function (Niwa & 
Ise, 1994). Niwa et al. (1997) suggested that IS is involved in the development of CRF, 
and that AST-120, an oral charcoal adsorbent that reduces the levels of circulating 
uremic toxins such as IS and indole acetic acid, can delay progression of the condition 
by reducing the serum and urine levels of IS in undialyzed uremic patients. 
 Morisaki et al. (2008) found that cisplatin-treated rats exhibited a marked 
decrease in body weight compared with the untreated control group. Furthermore, the 
levels of both BUN and SCr values were significantly elevated in cisplatin-treated rats 
compared with control rats, indicating AKI was induced by cisplatin administration. 
However, the changes in body weight, BUN and SCr levels in cisplatin-treated rats 
were significantly reduced by oral administration of AST-120. These results suggested 
that cisplatin-induced AKI is partially prevented by AST-120 administration, and that 
IS was involved in the AKI induced by cisplatin (Morisaki et al., 2008). As anticipated 
during cisplatin-induced AKI, endogenous IS levels in serum and kidney were 
markedly elevated. By contrast, the cisplatin-associated increase in the IS level in both 
serum and kidney was significantly suppressed upon administration of AST-120. 
Cisplatin treatment markedly suppressed mRNA levels of rOAT1 and rOAT3 in the 
kidney (Fig. 8). In contrast, cisplatin-treated rats administered with AST-120 exhibited 
significantly higher levels of rOAT1 and rOAT3 mRNA compared with 
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cisplatin-treated rats. The protein expression levels of rOAT1 and rOAT3 were greatly 
suppressed in cisplatin-treated rat kidney, whereas administration of AST-120 
partially restored the downregulation of rOAT1 and rOAT3 (Fig. 8). In 
cisplatin-treated rats, rMATE1 mRNA expression was significantly lower than that of 
control rats. However, administration of AST-120 to cisplatin-treated rats resulted in a 
slight recovery in the level of rMATE1 mRNA and protein (Morisaki et al., 2008). 
This suppression in the expression level of rMATE1 could be largely restored by 
administration of AST-120. Therefore, the expression of rMATE1 is likely to be 
regulated under cisplatin-induced AKI. Hence, IS appears to be involved in the 
regulation of rMATE1 expression. 
 IS appears to be a high-affinity substrate for rOAT1 and rOAT3 (Deguchi et al., 
2004, 2005). Therefore, an elevation of renal IS concentration in cisplatin-treated rats 
might be related to the downregulation of these transporters. IS may play a 
pathological role, at least in part, in the altered function and expression of organic ion 
transporters as a mediator. This proposal is supported by the finding that AST-120 can 
partially restore the decrease in function and expression of organic ion transporters 
during cisplatin-induced AKI (Morisaki et al., 2008). The fact that AST-120 prevented 
serum and renal accumulation of IS, in association with significant amelioration of 
renal function, suggest that IS should be involved, at least in part, in cisplatin-induced 
AKI. Thus, the downregulation of rOAT1 and rOAT3 caused by cisplatin could 
accelerate IS accumulation in both serum and kidney, thereby augmenting renal 
tubular injury and leading to a further reduction in the level of these transporters.
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 Prevention of cisplatin-induced AKI by concomitant administration of a 
molecular targeted drug has been reported. Imatinib (STI-571), a potent inhibitor of 
BCR-ABL tyrosine kinase, is clinically used for the treatment of Philadelphia 
chromosome-positive (Ph+) chronic myeloid leukemia (CML) and gastrointestinal 
stromal tumor. It has been suggested that leukocytic hOCT1 mediates the uptake of 
imatinib and the expression status of hOCT1 is an important determinant of the 
pharmacological response of imatinib in CML patients (Thomas et al., 2004; Wang et 
al., 2008). Tanihara et al. (in press) reported that imatinib markedly reduced 
cisplatin-induced cytotoxicity and platinum accumulation in OCT2-expressing 
HEK293 cells, but almost no change was detected in the cells expressing human 
MATE1, MATE2-K and rat MATE1. In rats, the renal accumulation of cisplatin 
together with the subsequent nephrotoxicity were significantly reduced after oral 
administration of imatinib. The oral imatinib significantly elevated the serum 
concentration of intravenously administered cisplatin. Histological examinations 
revealed that concomitant administration of imatinib clearly prevented severe renal 
injury, suggesting that imatinib ameliorates cisplatin-induced AKI by inhibiting the 
renal accumulation of cisplatin via OCT2.  
 CDDP-induced AKI is accompanied by disturbances in renal handling of 
electrolytes. In particular, hypomagnesemia has emerged as a common event 
associated with CDDP-induced AKI; 76% of patients became hypomagnesemic 
during CDDP treatment (Schilsky et al., 1982; Lajer & Daugaard, 1999). Mavichak et 
al. (1985) reported that abnormalities of magnesium (Mg) metabolism were induced 
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by CDDP administration in rats. In addition, abnormal renal handling of Mg persisted 
along with residual lesions in the S3 segment of the outer medullary nephrons, 
indicating that renal tubular reabsorption of filtered Mg is suppressed under 
CDDP-induced AKI (Yao et al., 2007). Alternatively, hypomagnesemia appeared to 
be involved in further deterioration of renal tubular dysfunction following treatment 
with CDDP. Yokoo et al. (in press) observed the up-regulation of the organic cation 
transporter rOCT2 in hypomagnesemic rats before CDDP administration, but not of 
rOCT1 or rMATE1 (Fig. 9). TEA uptake by renal slices from hypomagnesemic rats 
was significantly higher compared with that of control rats. Renal accumulation of 
CDDP was markedly increased in hypomagnesemic rats. It was proposed that 
hypomagnesemia could cause dehydration and up-regulation of rOCT2, enhancing 
renal accumulation of CDDP and the deterioration of AKI (Yokoo et al., in press).  
 
3.2.2. Uranyl nitrate 
 Uranyl nitrate (UN)-induced AKI is a well established experimental model for 
studying kidney function. Indeed, this method of inducing AKI is particularly 
attractive due the reproducibly, high survival rate, and relatively consistent 
interference of renal function. One of the proposed mechanisms in the pathogenesis of 
UN-induced AKI is its direct effect on hemodynamics with a subsequent decline in 
glomerular filtration rate. By using a single-pass flow of rat perfused kidney treated 
with UN, Tanigawara et al. (1990) reported that the uptake of PAH across the 
basolateral membranes decreased gradually, and that transport across the brush border 
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membranes remained unchanged after uranyl nitrate treatment. Secretion of TEA from 
cells to the lumen was initially impaired, followed by interference in the uptake of 
TEA from blood to the cells. Using rats with UN-induced AKI, Shim et al. (2009) 
demonstrated that the expression level of OCT2 mRNA and protein in the kidney 
medulla appeared to decrease, although mRNA expression of the other OCTs was not 
appreciably affected. The plasma level of testosterone, a suggested modulator of 
OCT2 expression at the transcription level, was unchanged, suggesting that the 
downregulation of OCT2 is testosterone-independent. During AKI the steady state 
tissue-to-plasma ratio of TEA decreased in the kidney medulla by approximately 
15-fold. The reduced OCT2 expression in the kidney medulla resulted in a lower 
distribution of TEA within the kidney medulla. Thus, the renal clearance of TEA in 
UN-induced AKI rats was less than that in normal rats. 
 
3.2.3. Inorganic mercury 
 Inorganic mercury accumulates preferentially in the kidney, inducing AKI, 
which is characterized by profound renal vasoconstriction, reduction in glomerular 
filtration rate and histological injury. Renal tubular cells represent the primary target 
where highly reactive inorganic mercuric ions are rapidly accumulated, inducing cell 
injury (Zalups 2000). Several factors may account for this susceptibility, including the 
specific transport systems mediating the uptake of mercuric ions by the renal tubular 
cells (Bridges and Zalups. 2004). In rats with HgCl2-induced AKI, OAT1 protein 
expression significantly increased in the homogenates and decreased in the basolateral 
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membranes from kidneys. The exposure to HgCl2 also decreased the expression of 
OAT1 mRNA (Di Giusto et al., in press). The increased OAT1 expression in 
homogenates suggested impairment of its degradation, which could be mediated by the 
mercury toxicity-dependent inhibition of some specific proteins/enzymes underlying 
the mechanisms of OAT1 degradation and/or turnover (Zalups 2000). The expression 
of OAT3 at both the protein and mRNA level was reduced in the kidneys of 
HgCl2-treated rats, indicating downregulation at the transcriptional level. A much 
greater reduction in the level of OAT3 mRNA (60%) was observed by comparison 
with the reduction in the level of OAT3 protein (30%) in homogenates, suggesting an 
alteration in the degradation pathway. Because OAT1 and OAT3 are thought to 
mediate the accumulation of mercuric compounds in the proximal tubular cells, their 
downregulation might be one defensive mechanism to protect the kidney against 
mercury-induced injury. Thus, the pharmacological modulation of the expression 
and/or the function of OAT1 and OAT3 might be an effective therapeutic strategy for 
reducing the nephrotoxicity of mercury. 
 
4. Perspective 
 Functional and transcriptional regulation of renal SLC22A transporters implies 
that these proteins play an essential physiological role in homeostasis and/or 
detoxification. Recently, Ahn & Nigam (2009) have proposed a “remote sensing and 
signaling hypothesis” for communication between different organs expressing organic 
anion transporters. Namely, factors that impair the clearance of substrates by the OAT 
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transporters, such as toxins, ischemia or competitive inhibition by other substrates, 
could disrupt OAT function, thereby leading to perturbed homeostasis. To compensate 
for the loss of function of OATs and to restore homeostasis, upregulation and/or 
activated function of other transporter isoforms may occur at the transcriptional, 
translational or post-transchemical level, either in the injured kidney or other tissues 
involved in a remote sensing network. Although a great deal of information 
concerning the regulation of renal SLC22A transporters has been accumulated, the 
mechanisms based on the altered molecular and functional regulation of renal 
SLC22A transporters accompanied by ischemia or toxicant-induced AKI still remains 
to be elucidated. Understanding of such regulatory mechanisms and inter-organ 
communication network of SLC22A transporters would provide information for their 
physiological and pharmacological functions in maintaining systemic homeostasis in 
AKI.  
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Legends for Figures 
Fig. 1. Schematic representation of membrane transporters in renal proximal tubules. 
BBM, brush-border membrane; BLM, basolateral membrane; OA-, organic anion; 
OC+, organic cation; α-KG, α-ketoglutarate; NHE, sodium/proton exchanger. 
Arrows indicate the direction of movement of substrates and ions via each 
transporter.  
 
Fig. 2. Dominant negative mutant of dynamin 2 blocked constitutive and 
PKC-modulated OAT1 internalization. cDNA plasmid encoding human 
OAT1-tagged with myc at its C terminus was transfected into COS-7 cells. 
OAT1-expressing cells underwent biotinylation with sulfo-NHS-SS-biotin at 4°C. 
Following biotinylation, one set of cells was washed with PBS and kept at 4°C to 
determine the total initial surface OAT1 and stripping efficiencies. a, top panel: 
cells were transfected with cDNA encoding dominant negative mutant of 
dynamin-2 (Dyn-2 mutant). 48 h later, OAT1 internalization (15 min) was 
analyzed in the presence and absence of 1  μM PMA followed by Western blotting 
using anti-myc antibody (1:100). Bottom panel: as a loading control for the top 
panel, total expression of OAT1 in cell lysate was measured using anti-myc 
antibody (1:100). b, densitometry plot of results from a, top panel as well as from 
other experiments. Internalized OAT1 was expressed as a percentage of total 
initial cell surface OAT1 pool. c, the effect of Dyn-2 mutant on the expression of 
OAT1 at the cell surface, intracellular compartments, as well as in total cell lysates. 
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d, [3H]PAH uptake into cells transfected with Dyn-2 mutant. Uptake activity was 
expressed as a percentage of the uptake measured in the control cells. (Reprinted 
from Zhang et al., 2008). 
 
Fig. 3. Schematic model of transcriptional regulation of the human OAT1 gene. In the 
abundance of HNF-4, HNF-4 transactivates human OAT1 promoter activity via 
DR-2 and IR-8 elements. IR-8 contributes to the activation by HNF-4 more than 
DR-2 (HNF-4 overexpression). Under normal conditions, IR-8 is responsible for 
the basal promoter activity of OAT1, and HNF-4 binds to IR-8 (constitutive 
expression). (Reprinted from Ogasawara et al. (2007) with permission from 
American Physiological Society). 
 
Fig. 4. Proposed model for the regulatory mechanism of organic anion transport 
mediated by organic anion transporter 3 (OAT3). Phenylephrine (PE) stimulates 
PKC leading to downregulation of OAT3 by an unknown mechanism(s). As 
shown in previous studies and the present study, EGF stimulates OAT3 activity via 
MAPK, MEK and ERK1/2, which activates PLA2 leading to the release of 
arachidonic acid (AA). AA is then metabolized to prostaglandins (PGE2), which 
activates PKA via adenylate cyclase and finally stimulates OAT3 by an unknown 
mechanism(s). (Reprinted from Soodvilai et al. (2004) with permission from 
American Physiological Society). 
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Fig. 5. Schematic model of transcriptional regulation of the human OAT3 gene. 
CREB-1 and ATF-1 bind to CRE and activate the transcription of the OAT3 gene 
(constitutive expression). PKA further activates the transcription of the OAT3 
gene through phosphorylation of both CREB-1 and ATF-1 (inducible expression). 
(Reprinted from Ogasawara et al. (2006) with permission from American Society 
for Pharmacology and Experimental Therapeutics). 
 
Fig. 6. Trans-activation of ARE-mutated rOCT2 promoters by rAR in the presence of 
testosterone. Constructs were transiently transfected into LLC-PK1 cells with rAR 
and pRL-TK. The cells were cultured for 43 h with vehicle or 1 μM testosterone, 
and luciferase activity was then measured. Firefly luciferase activity was 
normalized to Renilla luciferase activity. Black diamonds indicate AREs. *P < 
0.05, significantly different from control. (Reprinted from Asaka et al. (2006) with 
kind permission from Springer Science+Business Media). 
 
Fig. 7. Protein and mRNA expression of basolateral organic ion transporters in the 
kidney of sham-operated and I/R rats. A, antisera specific for rOAT1, rOAT3, 
rOCT1, rOCT2 or β-actin were used as primary antibodies. B, ratio of rOAT1, 
rOAT3, rOCT1 and rOCT2 density to β-actin density in sham-operated (□) and I/R 
(■) rats. The values for sham-operated rats were arbitrarily defined as 100%. C, 
mRNA expression of basolateral organic ion transporters in the kidneys of 
sham-operated and I/R rats. rOAT1, rOAT3, rOCT1 and rOCT2 mRNA 
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expression levels in sham-operated (□) and I/R (■) rats were determined by 
real-time PCR analysis. The relative amounts of rOAT1, rOAT3, rOCT1 and 
rOCT2 mRNA were normalized to that of 18S ribosomal RNA. ***P < 0.001 
versus sham-operated rats. (Reprinted from Matsuzaki et al. (2008) with 
permission from American Society for Pharmacology and Experimental 
Therapeutics).  
 
Fig. 8. mRNA and protein expression of rat organic anion transporters in the kidneys 
of control and cisplatin-treated rats with or without AST-120. mRNA expression 
levels of (A) rOAT1 and (B) rOAT3 in control and cisplatin-treated rats with or 
without AST-120 were determined by real-time PCR analysis. (C). *P<0.05, and 
**P< 0.01, significantly different from control rats. #P<0.05, and ##P<0.01, 
significantly different from cisplatin-treated rats. (Reprinted from Morisaki et al. 
(2008) with kind permission from Springer Science+Business Media).  
 
Fig. 9. Protein expression levels of transporters in the kidneys of the control group and 
low Mg group at 0 and 120 h after the administration of cisplatin (3 mg/kg). 
Immunoblotting was performed by using antiserum specific for rOCT1, rOCT2 
and rMATE1 as primary antibodies (a). Relative band intensities were quantified 
by densitometry for the protein expression levels of rOCT1 (b), rOCT2 (c) and 
rMATE1 (d). *P<0.05, **P<0.01, significantly different from the control group at 
the same period. †P<0.05, significantly different from the control group at 0 h. 
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##P<0.01, significantly different from the control group at 0 h. (Reprinted from 
Yokoo et al. (2008) with kind permission from Springer Science+Business 
Media).  
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